Skip to main content

News & Press Releases

Filter by:

News Thumbnail MLS
Vice President of ML Strategies Christian Fjeld was quoted in an article published by Legaltech News on the National Highway Traffic Safety Administration’s approval of robotics company Nuro’s request for three exemptions to deploy its fully autonomous car fleet in the United States.
News Thumbnail MLS

Op-Ed: A 2020 Call To Action On Medical Devices

February 6, 2020 | Boston Business Journal

Senior Director of ML Strategies Aaron L. Josephson authored an op-ed published by the Boston Business Journal about opportunities to shape medical device public policy in 2020, including user fees, user fee riders, and Collaborative Communities.
News Thumbnail MLS
On December 9, 2019, Vice President of ML Strategies Christian T. Fjeld participated in the Artificial Intelligence (AI) & Business Table of Experts discussion hosted by the San Francisco Business Times. During the forum, panelists addressed how businesses can leverage AI to drive innovation, the impact AI will have on the economy and on society, and the meaning of artificial intelligence itself.
In this Q&A published by Legaltech News, Vice President of ML Strategies Christian Fjeld—former lead Democratic Senate staffer tasked with shepherding the American Vision for Safer Transportation through Advancement of Revolutionary Technologies Act (AV START Act) through the Senate—discussed why Congress failed to pass the AV START Act, how autonomous vehicles’ complexity isn’t lawmakers’ largest hurdle, and why the data privacy debate may factor into the next autonomous vehicle bill.
News Thumbnail MLS
An article published by Inside Health Policy quoted Aaron Josephson, Senior Director at ML Strategies, on Senators Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) letter to U.S. Food and Drug Administration (FDA), requesting information about the FDA's upcoming guidance clarifying the distinction between remanufacturers and servicers.

News Thumbnail MLS
MedTechDive reported that the U.S. Food and Drug Administration is not yet ready to go to Congress to seek new powers for its evolving precertification pilot for software, but it will need new authorities to determine how the experimental path fits into the current regulatory scheme. The article included commentary from Senior Director of ML Strategies Aaron Josephson and Mintz Associate Benjamin Zegarelli.

Follow ML Strategies